Articles related to CLINICAL TRIALS

The phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy significantly improved OS compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma.

Although vaccinations to the arm can still prevent serious illness, their ability to ward off infection completely has been diminished. And part of the reason may be the location of the vaccines, which some scientists now want to change by delivering inoculations to the site where the virus first makes contact: the nose. Three separate nasal sprays, now in advanced trials, could trigger stronger immune responses in people who have COVID-19.

A new case study that analyzed the correlation between the use of antidepressants and suicide concluded that all patients treated with antidepressants should receive careful monitoring for clinical worsening, suicidality, or unusual changes in behavior.

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.

Results of a MEDLINE review highlight numerous studies across different cancer types indicating that ctDNA-based MRD detection predicts recurrence with high sensitivity and specificity, and with lead times that precede standard imaging by up to 12 months.

Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) might be used to identify patients who would benefit more from standard-of-care adjuvant chemotherapy by accurately assessing recurrence-risk post-surgery and by evaluating adjuvant chemotherapy efficacy. This analysis from the GALAXY study, an observational study monitoring MRD, evaluates the association of ctDNA dynamics with a short-term clinical outcome and ACT efficacy.